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Introduction: Patients with febrile neutropenia (FN) exhibit changes in extracellular fluid that may alter the plasma
concentrations of beta-lactams and result in therapeutic failure or toxicity. We evaluated the pharmacokinetics of
piperacillin/tazobactam in patients with hematological malignancies and FN after receiving chemotherapy at a
primary public cancer center.
Methods: This was an open, nonrandomized, observational, descriptive, and prospective study. Samples from 15
patients with hematological malignancies and FN were evaluated after the administration of chemotherapy. Five
blood samples were taken from each patient when the antibiotic level was at steady-state 10, 60, 120, 180, and 350
min after each dose. Antibiotic concentrations were measured using gel diffusion with Bacillus subtilis. All study
participants provided written informed consent.
Results: We investigated the pharmacokinetics of piperacillin in 14 patients between the ages of 18 years and
59 years and with a mean absolute neutrophil count of 208 cells per mm3 (standard deviation (SD) ± 603.2). The
following pharmacokinetic measurements were obtained: maximum concentration, 94.1–1133 mg/L; minimum
concentration, 0.47–37.65 mg/L; volume of distribution, 0.08–0.65 L/kg (mean, 0.34 L/kg); drug clearance (CL),
4.42–27.25 L/h (mean, 9.93 L/h); half-life (t1/2), 0.55–2.65 h (mean, 1.38 h); and area under the curve,
115.12–827.16 mg · h/L.
Conclusion: Patients with FN after receiving chemotherapy exhibited significant variations in the pharmacokinetic
parameters of piperacillin compared with healthy individuals; specifically, FN patients demonstrated an increase in
t1/2 and decreased CL.
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Hematological malignanciesBackground
Variations in the pharmacokinetic (PK) and pharmaco-
dynamic (PD) parameters of hydrophilic antimicrobial
agents have been described previously in different patho-
logical conditions (e.g., sepsis, trauma, burns, hypoalbumin-
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reproduction in any medium, provided the orfebrile neutropenia (FN). These variations were identi-
fied because the extracellular fluid (ECF) levels in these
patients were different than in healthy patients. Changes
in ECF levels affect the plasma concentrations of
antibiotics [1,2].
Beta-lactams are the first-choice antibiotics for the treat-
ment of FN after chemotherapy, and inadequate serum
levels of these antibiotics may lead to therapeutic failure.
Cefepime, piperacillin/tazobactam, imipenem/cilastatin,
and meropenem are beta-lactam antibiotics that exhibit
activity against Pseudomonas aeruginosa, and theseLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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empirical treatment of FN after chemotherapy [3].
Little information is available on the kinetic behavior
of piperacillin or the piperacillin/tazobactam combination
in cancer patients. However, addition of piperacillin or
amikacin to moxalactam administration in FN patients
has been shown to alter PK parameters compared with
healthy individuals [4], and a randomized clinical trial
evaluating PK parameters demonstrated a decrease in the
volume of distribution (Vd) and drug clearance (CL) and
an increase in half-life (t½) [5].
We investigated the PK parameters of piperacillin in
Latin American patients with hematological malignancies
and FN after receiving chemotherapy.
Methods
We conducted an open, nonrandomized, observational,
descriptive, and prospective study in the Hematology
Department of the National Cancer Institute (NCI) in
Bogota, Colombia. The Ethics Committees of the National
University of Colombia and NCI approved the protocol.
All study participants provided written informed consent.
Patients
The inclusion criteria were patients: aged >18 years with
a de novo diagnosis or recent diagnosis of hematological
malignancy; currently undergoing chemotherapy; who
had FN after receiving chemotherapy; did not have renal
or liver failure; being treated with piperacillin/tazobactam
(4.5 g, i.v.) every 6 h in the event of FN. Pregnancy tests
were negative for women of reproductive age.
The exclusion criteria were patients: with chronic kidney
disease defined as a estimated glomerular filtration rate
(eGFR) <60 mL/min/1.73 m2 [6]; with liver failure defined
as Child–Turcotte–Pugh classes B or C [7]; who received
combined antimicrobial therapy due to a polymicrobial
bloodstream infection.
Definitions
Neutropenia was defined as an absolute neutrophil
count <1,000 cells per mm3 or in cases where a count
<1,000 cells per mm3 was anticipated 3–5 days after
chemotherapy. Neutropenia was also declared in cases
of acute leukemia with a neutrophil count with a blast
percentage >90%.
Fever was defined as a temperature of 38°C for 1 h or
one temperature measurement >38.3°C. FN was second-
ary to intensive antineoplastic induction, re-induction,
or maintenance chemotherapy.
Laboratory tests
Five samples were taken from each of the 15 patients 10,
60, 120, 180, and 350 min after the dose of piperacillin/
tazobactam attained a steady state. Piperacillin/tazobactamwas administered as a generic product (Vitalis®) purchased
by the institution for use in all patients. The piperacillin
content in samples from different batches and patient sera
was measured using a biological gel diffusion assay with
Bacillus subtilis ATCC 6633. The following PK parameters
were calculated from the concentration–time plots:
maximum concentration (Cmax), minimum concentra-
tion (Cmin), Vd, CL, t½, and the area under the curve
(AUC0–∞).
Statistical analyses
STATA IC® ver11.1 software was used for analyses.
Two-tailed Student’s t-tests were used to compare inde-
pendent samples at a significance defined as p < 0.05. PK
parameters were compared between group of patients
with albumin levels >3 g/dLvs. those with <3 g/dL, those
who received a piperacillin/tazobactam in bolus dose, and
those who received chemotherapy with Hyper-CVAD vs.
another chemotherapy regimen (for Hyper-CVAD chemo-
therapy, course A comprised cyclophosphamide, vincris-
tine, doxorubicin and dexamethasone, and course B
consisted of methotrexate and cytarabine).
Results
Originally, the study cohort was 15 patients. However, 1
patient (patient 003) was excluded because the inhibition
zone was not clearly visible due to serum hyperviscosity
and the white blood cell (WBC) count was 262,400 cells
per mm3. The ages of the 14 studied patients ranged
from 18 years to 59 years (mean, 31.9 years; standard
deviation (SD), 15.4), and 8 of the patients were women.
The albumin values recorded were between 2.1 g/dL and
4 g/dL (mean, 3.04 g/dL; SD, 0.56), and the neutrophil
count was 0–2,380 cells per mm3 (mean, 208 cells/mm3;
SD, 603.2). In 71.4% of patients, the Hyper-CVAD
chemotherapy regimen was used alone or in combin-
ation with rituximab or imatinib (Table 1).
Concentrations (μg/mL) versus time were plotted for
each patient to generate an exponential curve, which
was used to calculate PK parameters. Visual inspection
revealed one-compartment model behavior of piperacillin/
tazobactam. Table 2 presents the PK parameters for each
patient.
Statistically significant differences in PK parameters
were evaluated by comparing the albumin values (Table 3)
in patients with levels <3 g/dL and >3 g/dL and the use of
Hyper-CVAD chemotherapy against other regimens.
Discussion
The present study confirmed previous observations of dif-
ferences in the PK parameters of piperacillin/tazobactam
in patients with FN and cancer. Patients with cancer
and FN after chemotherapy are prone to cachexia, hy-
poalbuminemia, and the development of a third space
Table 1 General characteristics of patients
Parameter Number (%)
Age (years)
18– 24 7 (50.0)
25 - 31 3 (21,4)





40 - 50 5 (35.7)
51 – 60 6 (42.9)
61 - 80 3 (21.4)
Mean ± SD = 56.4 ± 11.2
Height (cm)
150 – 160 9 (64.3)
161 – 170 4 (28.6)
171 – 180 1 ( 7.1)
BMI kg/m2
17.0 – 22.0 8 (57.2)
22.1 – 27.0 5 (35.7)
27.1 – 32.0 1 (7.1)
Mean ± SD = 21.9 ± 4.0
Creatinine clearance (mg/mL)
80 - 110 3 (21.4)
111 - 140 6 (42.9)
141 - 170 5 (35.7)
Albumin g/dL
2.0 – 2.6 3 (21.4)
2.7 – 3.3 7 (50.0)
3.4 – 4.0 4 (28.6)
Mean ± SD = 3.0 ± 0.6





Lymphoid leukemia 9 (64.3)
Myeloid leukemia 3 (21.4)
Number of neutrophils/mm3
Range 0–2380
Mean ± SD 208(603.2)
Therapy cycles
1 – 2 6 (42.9)
3 – 5 3(21.4)
6 - 8 5 (35.7)
Table 1 General characteristics of patients (Continued)
FN-associated chemotherapy
Hyper-CVAD 10 (71.4)
No Hyper-CVAD 4 (28.6)
BMI, body mass index; FN, febrile neutropenia; GFR, glomerular filtration rate.
For Hyper-CVAD chemotherapy, course A comprised cyclophosphamide,
vincristine, doxorubicin and dexamethasone, and course B consisted of
methotrexate and cytarabine.
Mentioned on page 6.
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favors drug binding to proteins, which slows distribu-
tion of the drug in the systemic circulation, decreases
Cmax and increases t1/2.
The current study, in which piperacillin/tazobactam
was administered as a bolus dose every 6 h, confirmed
that the Cmin, elimination rate (Ke), and t1/2 parameters
of piperacillin/tazobactam were modified in patients
whose albumin levels were <3 g/dL. However, patients
with an albumin level <3 g/dL would be expected to ex-
hibit a higher free faction of antibiotic and a higher CL
because these two parameters are directly related (renal
CL = unbound drug × eGFR) [8]. Indeed, a difference in
GFR was observed between subgroups because this rate
increased in patients with albumin levels > 3 g/dL. How-
ever, other statistically significant differences between
these groups were not observed. Organ function can
be diminished in patients with lower albumin levels.
For example, kidney function may increase tumor pro-
gression or decrease functional reserve, and non-renal
CL or other non-quantified clinical variables may also
be altered.
Table 4 summarizes the values of the means and SD
for the calculated PK parameters and other patient char-
acteristics in comparison with the work of Drusano et al.
[4], Drusano et al. [5] and Mattoes et al. [9].
Analyses of the piperacillin/tazobactam concentration
against time plots revealed a one-compartment model,
as described previously in an in vitro study by Strayer
et al. [10]. The PK parameters of piperacillin alone at
3 g every 6 h were compared with those of 3 g piperacil-
lin every 6 h or 4 g every 8 h in combination with
0.375 g or 0.5 g tazobactam, respectively (Table 3). The
PK parameters in our FN patients were related directly
to higher Vd and CL values, which explains the similar t1/2
value as that observed by Strayer et al. (Table 4) [10].
A one-compartment model of behavior was observed
previously when piperacillin/tazobactam was administered
as a prolonged infusion to 13 patients who were hospital-
ized for the treatment of an infectious process [11]. Of
these patients, 6 were noncritical and 7 were critical, and
they received 4.5 g of piperacillin/tazobactam as a 4-h
intravenous infusion every 8 h. These previous results by
Shea et al. [11] suggested that the lower t1/2 value was due
Table 2 PK parameters for each patient
Patient Cmax (μg/mL) Cmin (μg/mL) VD (L/kg) Ke (h
–1) CL (L/h) t1/2 (h) AUC [0-inf] Dose in mg/kg
1 283.97 13.29 0.26 0.53 7.45 1.31 398.78 54.05
2 200.56 16.87 0.35 0.44 8.70 1.59 419.14 52.63
4 337.21 6.36 0.22 0.69 8.15 1.01 232.15 70.18
5 211.53 18.76 0.35 0.43 8.19 1.60 446.61 46.51
6 153.13 18.74 0.61 0.36 9.30 1.95 311.08 85.11
7 97.37 3.88 0.52 0.57 23.54 1.21 163.28 63.49
8 94.10 2.22 0.65 0.64 27.25 1.08 115.12 58.82
10 465.78 13.64 0.15 0.57 4.93 1.21 607.15 86.96
11 162.34 5.18 0.42 0.53 13.13 1.30 317.32 66.67
12 179.52 37.65 0.45 0.26 5.84 2.65 418.48 60.61
13 318.81 28.34 0.26 0.44 5.48 1.59 667.45 62.50
14 319.55 19.07 0.30 0.50 6.20 1.40 477.15 78.43
15 513.74 4.52 0.10 0.82 6.38 0.85 678.99 86.96
16 1133 0.47 0.08 1.25 4.42 0.55 827.16 66.67
Mean 319.33 13.50 0.34 0.57 9.93 1.38 434.28 67.11
σ(n-1) 266.08 10.71 0.18 0.24 6.95 0.51 205.17 13.01
Mentioned on page 6.
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ters (Table 4) [11].
Piperacillin doses between 8 g per day and 18 g per
day were administered with tazobactam to four groups
of healthy patients. Auclair et al. found that one-
compartment model behavior was determined by visual
inspection of the logarithmic relationship of plasma
and urinary concentrations against time [12]. Piperacil-
lin elimination is accomplished primarily via active
tubular secretion by the kidney, but elimination is
assisted by glomerular filtration and biliary excretion.
Saturation of these mechanisms at plasma concentra-
tions of piperacillin/tazobactam is unlikely. A nonlinear
elimination, as explained by the Michaelis–Menten
equation, would occur in the event of saturation, which
would require a different PK analysis (Table 4) [12].
The filtration rate of a drug and the subsequent elimin-
ation rate are dependent upon the volume of the glom-
erular filtrate and free drug concentrations in the
plasma (Table 4) [13].
One limitation of this study was the lack of a standard-
ized method for administration of piperacillin/tazobactam
by nurses with regard to the reconstitution of the powderTable 3 PK parameters in patients with albumin >3 g/dL and




Mentioned on pages 6 and 8.forms of the drugs, solvent volume, or rate of infusion
of the diluted antibiotic. This variability underlies repre-
sentation of the concentration–time plots for antibiotic
administration as an infusion in some patients and a
bolus in others. Therefore, calculations of PK parame-
ters were undertaken using interpretations of these two
modes of drug administration. Mattoes et al. [10] in-
vestigated 12 healthy adults who received piperacillin/
tazobactam (4.5 g, i.v.) every 6 h and demonstrated
that patients with FN exhibited higher values of Vd
and lower values of CL. These results may explain the
lower values of Ke and higher values of t1/2 as com-
pared with healthy individuals. PK parameters were in-
vestigated in patients in the intensive care unit (ICU)
after administration of a 4-g bolus of piperacillin every
8 h or a 4-g bolus with subsequent continuous 8-g
infusion for 24 h. PK parameters in patients who re-
ceived a bolus administration compared with patients
with FN in our study exhibited a similar value of CL
and lower value of Vd, which would explain the lower
t1/2 value compared with ICU patients. Langgartner
et al. found that PK parameters often differed in
healthy subjects because a previous study found that<3 g/dL with statistically significant differences




Table 4 Summary of PK parameters for piperacillin/tazobactam as compared with other studies






Cmax (μg/mL) 319.3 ± 266.08 366.7 108.2 ± 31.7 SD 282.2 ± 57.7 231 ± 66 152 SD
Cmin (μg/mL) 13.5 ± 10.71 SD 27.6 ± 26.3 SD SD 11.5 ± 14.8 12 SD
VD (L/kg) 0.34 ± 0.18 SD 0.28 ± 0.07 0.12 0.2 34.6* 0.21 ± 0.14 0.13 ± 0.03
Ke (h–1) 0.57 ± 0.24 SD SD SD 0.86 ± 0.09 SD SD SD
CL (L/h) 9.93 ± 6.45 SD 8.6 ± 3.0 7.8 10.9 ± 2.5 10.23 8.31 ± 3.39 6.1 ± 2.54
t1/2 (h) 1.38 ± 0.51 1.3 2.1 ± 1.2 0.9 0.81 ± 0.08 2.4 ± 1.2 1.47 ± 0.95 1.54 ± 0.42
AUC[0–∞) mg•h/L 434.28 ± 205.17 488.9 527.5 ± 216.1 290 380.4 ± 72.6 391 ± 183 635.3 ± 253.2 SD
Weight (kg) 56.4 ± 26.78 In vitro 79.6 ± 13.8 SD 69.8 ± 15.7 60 - 86 69.5 70.2 ± 29.05
*Data shown in L.
Mentioned on pages 7, 8 and 9.
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creased clearance of creatinine (Table 4) [14].
In another study, moxalactam was administered to FN
patients and piperacillin or amikacin were included ran-
domly. Drusano et al. measured the following PK parame-
ters for piperacillin: Vd = 0.21 (SD = 0.14) L/kg; CL = 8.31
(SD 3.39) L/h/1.73 m2; and t1/2 = 1.47 (SD = 0.95) h
(Table 4) [4]. Furthermore, Drusano et al. conducted a
randomized, double-blind clinical trial in which one group
received piperacillin and amikacin and the other group re-
ceived imipenem/cilastatin. PK parameters were measured
and decreases were found in Vd (0.13 (SD = 0.03) L/kg)
and CL (6.1 (SD = 2.54) L/h/1.73 m2) and an increase in
t1/2 (1.54 (SD = 0.42) h) noted [5].
Conclusions
We found that piperacillin/tazobactam exhibited a one-
compartment model of PK behavior in neutropenic pa-
tients. These data are in accordance with those of previous
reports.
FN patients after chemotherapy exhibited important
variations in PK parameters compared with healthy in-
dividuals. FN patients exhibited an increase in t1/2 and
a decrease in CL.
FN patients should receive piperacillin/tazobactam
doses based on weight (75 mg/kg) due to the low weight
of these FN patients and the observed variations in
plasma concentrations.
Study limitations
One important limitation of this study was the inability to
standardize the infusion rate or the amount of piperacillin/
tazobactam diluent. This variation caused the values of
plasma concentrations of antibiotics to differ from the
expected values over time in some patients. This problem
necessitated evaluation of the exponential curves from
which the PK parameters were calculated with fewer
samples than were taken. Serum sample measurements
for piperacillin/tazobactam corresponded to those fordifferent batches from the same drug company, but the
piperacillin content in one sample from a different
batch was not significantly different (results to be
published).
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